Enterprise Equity
VC Fund
Dundalk, Ireland
Enterprise Equity (or EEVC) is an excellent for providing capital to early stage and expanding business throughout Ireland.
- Total investments:
- 51
- Last investment:
- Lead investor:
- 10%
Last updated:
For AI agents: llms.txt
Industries Enterprise Equity invests in
SoftwareInformation TechnologyHealth CareMedical DeviceManufacturing
Stages Enterprise Equity invests in
Funding RoundSeedSeries BSeries ASeries D
Countries Enterprise Equity invests in
IrelandUnited StatesUnited KingdomLuxembourg
Round sizes
Seed $549k–$2.2MSeries B $2.6M–$7.5M
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $549k–$2.2M
- Series B
- $2.6M–$7.5M
Investment Focus
Industry
- Software 19 (37%)
- Information Technology 10 (20%)
- Health Care 8 (16%)
- Medical Device 8 (16%)
- Manufacturing 7 (14%)
Stage
- Funding Round 24 (47%)
- Seed 11 (22%)
- Series B 5 (10%)
- Series A 4 (8%)
- Series D 2 (4%)
Country
- Ireland 31 (61%)
- United States 6 (12%)
- United Kingdom 4 (8%)
- Luxembourg 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Frank Walsh
Partner and Director
|
Partner and Director | Total investments: 4 | Find email | |
Hiroshi Okamoto
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
Regina Lane
Accounts and Compliance Manager
|
Accounts and Compliance Manager | Total investments: 0 | Find email | |
Rory Hynes
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
Akira Sato
Venture Partner
|
Venture Partner | Total investments: 2 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Phorest
|
Phorest was founded by Ronan Perceval and is one of the leading online booking providers to the hair and beauty industry in the UK and Ireland. Phorest operates a web based salon management tool for salons and an online booking service for consumers called zanadoo.me. In 2010, Phorest processed 6.4m salon bookings for 500,000 people. | $21.9M / Private Equity / Jun 16, 2018 | |
Metabolomic Diagnostics
|
Metabolomic Diagnostics is a deep-tech company specialized in the development of novel biomarker based diagnostic solutions for complex diseases. The company has developed an effective pipeline to firstly identify diagnostic biomarker panels and then translate these panels into clinical assays ready for application in the clinical laboratory.Thispipeline combines the biomarker multiplexing capabilities of Mass Spectrometry, a powerful analytical technology, with the company’s own informatics and statistics solutions to deliver diagnostic innovation. This is reflected in Metabolomic Diagnostics’ strong and versatile IP portfolio of technical innovations and biomarkers.Our VisionMetabolomic Diagnostics’ primary vision is to develop a portfolio of diagnostic solutions which can determine, early in a woman’s pregnancy,her risk of developing major complications much later in her pregnancy and thus enabling personalized care, adapted to each woman’s individual needs. Pregnancy complications like preeclampsia, gestational diabetes, preterm birth, and in-uterine growth restriction, all have the potential to severely impact on the well-being of mother and child.The company’s innovative diagnostic solutions will assist clinicians in re-imagining how these conditions are managed: our novel risk assessment tools are specifically developed in conjunction with prenatal care providers to ensure they make a difference that really matters. This in turn will enable clinicians to improve pregnancy outcomes globally.Our solutions will empower pregnant women: accurate pregnancy risk information will allow a pregnant woman, in partnership with her care provider, to determine what prenatal care is best for her pregnancy. | $2.2M / Grant / May 16, 2018 | |
SurgaColl
|
SurgaColl Technologies is a medical device company developing novel tissue regeneration products for the surgical treatment of diseases of the bone, cartilage and other human tissue. Based on technology developed at the Tissue Engineering Research Group (TERG) of the Royal College of Surgeons in Ireland (RCSI), headed by Professor Fergal O’Brien,the company aims to become a leader in the field of regenerative medical devices. | $4.1M / Series A / Jan 01, 2018 | |
Swrve
|
Swrve is the world's leading mobile marketing automation platform, pioneering the fast-growing mobile engagement marketing space.We are also proud to be the first mobile marketing company to combine predictive analytics with messaging for mobile apps in our Predictive Marketing Suite, which employs a continuously updated behavioralalgorithm that determines an app user’s propensity for action or inaction. Swrve combines class-leading analytics, segmentation, AB testing and in-app messaging in a unified application that allows marketing managers to continually test their applications by tracking user behavior, targeting specific user segments, tuning in-app elements, and talking to users via in-app messages. In the first half of 2015, Swrve signed more than 40 new clients in a wide range of industries from retail, travel, hospitality, banking and insurance to sports, media, entertainment, games, and lifestyle. Among the notable customer wins were The Guardian, Condé Nast, Glamsquad, Warner Brothers, Microsoft, and Backflip. As a result, our global bookings in the second quarter of 2015 increased 33% over the previous quarter and 153% over Q4 2014.In 2015, Swrve also ranked #420 in Inc. magazine’s 34th annual Inc. 500, an exclusive ranking of the nation's fastest-growing private companies. The company is headquartered in San Francisco, California and was founded by Hugh Reynolds and Steven Collins in 2010. | $25M / Series D / Sep 14, 2017 | |
Touch Press
|
Touch Press integrates the award-winning portfolios of three leading app developers to form a digital education and publishing powerhouse for the Touch Generation.The formation of Touch Press represents an unprecedented investment in educational games, apps, and reference content, with the objective of delivering a lifetime of learning content toconsumer and schools markets. The three portfolios comprise a truly unique suite of apps, delivering a contiguous collection of content from kindergarten through middle-school and beyond. | $10M / Jan 22, 2017 | |
TreeMetrics
|
TreeMetrics offers a 3D measurement system to measure standing trees in forests.The company’s TreeMetrics software automatically creates DBH, basal area, stocking, volume per tree, volume per hectare, tree height, taper measurements, and stem files. It enables growers to sell their trees at an optimum representative price and for purchasers toimprove their product recovery.TreeMetrics was founded in 2005 and is based in Cork, Ireland. | Apr 04, 2016 | |
Polecat
|
Polecat has offices in London, Bristol, New York and California. We are a rapidly growing UK and US based company, providing big data risk intelligence solutions to AAA rated global companies and institutions with a focus on the energy, health and finance sectors. Polecat is a leader within the risk management / risk intelligence big dataspace. As a very early entrant to automated analytics, Polecat has been delivering “big data” solutions before the term big data was coined. Some of our customers include companies such as Shell, Johnson & Johnson, KPMG, the UK’s National Health Services (NHS) and the Central Bank of Ireland. | $3.9M / Mar 01, 2016 | |
Veronica's Snacks
|
Delicious, Healthy Snacks. At Veronica’s they’re all about enjoying good healthy food – and that extends to snack-time. When you’re feeling peckish during the day, there’s nothing quite like the pleasure – for adults and children alike – of munching down on a freshly opened packet of crisps. | $510K / Seed / Feb 23, 2015 | |
Capsos Medical
|
Capsos’ ‘CapBuster’ solution is a balloon catheter and guidewire combination device that enables physicians to re-open the most resistant occlusions where a calcified cap has formed on the surface of the blockage. | $2.4M / Jan 29, 2015 | |
Embo Medical
|
Embo Medical is based in National University of Ireland. Embo is developing the first true one-shot (one device per vessel) vascular embolisation device. The product is aimed at the peripheral vascular embolization market, a market where physicians perform about 180,000 procedures per year worldwide. | $3.3M / Seed / Oct 06, 2014 | |
| See all 51 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
SaaS Investors
99,274 investors
Enterprise Investors
77,348 investors
Software Investors
50,021 investors
Health Care Investors
43,014 investors
Climate Investors
40,325 investors
Manufacturing Investors
24,696 investors
Medical Device Investors
11,047 investors
SaaS VC Funds
61,208 investors
Enterprise VC Funds
49,693 investors
FAQ
What does Enterprise Equity invest in?
Enterprise Equity invests primarily in Software, Information Technology and Health Care startups, most often at Funding Round and Seed stage. Most of the 51 investments tracked by Shizune back companies in Ireland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Enterprise Equity's check size?
Enterprise Equity typically joins rounds of $549k–$2.2M at Seed and $2.6M–$7.5M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Enterprise Equity participates in.
How do I contact Enterprise Equity?
Public channels for Enterprise Equity include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Enterprise Equity?
The team at Enterprise Equity includes Frank Walsh (Partner and Director), Hiroshi Okamoto (Venture Partner) and Regina Lane (Accounts and Compliance Manager), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
